Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Semax vs. Selank: The Cognitive Compound Group, Compared
For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Neither compound discussed here is approved by Health Canada or the FDA for the research applications described.
Last updated: July 2026
Semax and Selank are frequently treated as a matched pair — same research lineage, same era, same stabilizing engineering trick, often mentioned in the same sentence. That’s fair as far as it goes, but they do close to opposite jobs in the brain, their evidence pictures diverge in specific ways, and — somewhat surprisingly given their shared origin — their current regulatory paths aren’t identical either. This guide puts them side by side properly.
At a Glance
| Semax | Selank | |
|---|---|---|
| Derived from | ACTH(4-10) fragment | Tuftsin (immunoregulatory tetrapeptide) |
| Primary effect | Activating — alertness, cognitive engagement | Calming — anxiolytic, mood-stabilizing |
| Core mechanism | BDNF upregulation, monoamine modulation | GABA-A positive allosteric modulation, serotonergic effects |
| Russian approval basis | Approved 1994, cerebrovascular and cognitive indications | Completed Phase III trials, generalized anxiety disorder |
| Best-established use | Stroke recovery, cognitive decline, optic nerve conditions | Generalized anxiety disorder, neurasthenia |
| Typical timing | Morning only — activating profile can disrupt sleep | Flexible — morning or evening depending on objective |
| WADA status | Not on the Prohibited List as of April 2026 | Not independently confirmed either way |
Same Lab, Same Trick, Opposite Jobs
Both compounds trace back to the Institute of Molecular Genetics of the Russian Academy of Sciences, developed in the 1980s and 1990s respectively, and both share a specific engineering signature: a short Pro-Gly-Pro tripeptide extension added to stabilize the core active fragment and extend its functional lifespan in the body. That’s a genuine, real similarity — but it’s a shared construction technique, not a shared function.
Semax’s core fragment comes from ACTH, and it retains melanocortin receptor activity relevant to attention, learning, and memory, without the adrenal steroidogenic effects of full-length ACTH. Its dominant, best-established mechanism is BDNF upregulation — a real, specific, and relatively uncommon effect among small peptides, with real preclinical replication outside Russia.
Selank’s core fragment comes from tuftsin, an entirely different endogenous peptide with immunoregulatory origins. Its dominant mechanism is GABA-A receptor modulation — specifically enhancing GABA binding without engaging the same site benzodiazepines use, which is the basis for its reputation as calming without sedation or dependency risk.
The practical result: Semax tends to increase alertness and cognitive engagement, sometimes described as edgy or overstimulating at higher doses. Selank tends to reduce anxiety without noticeably impairing cognition, sometimes described as insufficiently activating on its own for demanding cognitive work. Each compound’s weakness is roughly the other’s strength, which is exactly why they’re so often combined rather than treated as substitutes for one another.
The Evidence Picture: Extensive Duration, Limited Western Validation — For Both
Semax and Selank share essentially the same evidence-quality situation, and it’s worth understanding as a shared pattern rather than assessing each compound in isolation.
Both have genuine, sustained Russian clinical development behind them. Semax has been an approved pharmaceutical in Russia since 1994, in continuous clinical use for stroke recovery, cognitive decline, and related neurological conditions for three decades. Selank has completed Phase III trials in Russia for generalized anxiety disorder — real, late-stage clinical development, not preliminary exploration.
Both come with the same specific, honest limitation. Russian clinical research from this era doesn’t consistently meet the design standards Western regulators require — smaller sample sizes, inconsistent blinding and placebo controls, and study data that isn’t always available in English. A frequently cited Selank trial comparing it to a benzodiazepine, for instance, exists in Western databases only as an abstract, with full study details difficult to access. This is a real, recurring problem across both compounds’ evidence bases, not a flaw specific to one.
Both have real preclinical replication outside Russia, extending and partially corroborating their respective mechanisms — Semax’s BDNF and neuroprotective effects, and more recently a novel opioid-receptor mechanism in spinal cord injury recovery; Selank’s GABAergic activity and BDNF-related protective effects in animal stress and memory models. Neither compound’s Western preclinical work resolves the human evidence-quality question above, but both provide genuine mechanistic support from outside the original Russian research tradition.
Regulatory Status: A Surprising Divergence, With an Important Caveat
Given how similar their origin stories are, it’s easy to assume Semax and Selank carry identical current legal status. As of 2026, that assumption is specifically wrong, and it’s worth understanding why — with a clear caveat up front: this entire section describes the United States’ compounding-pharmacy framework, which has no direct equivalent or bearing on Canadian legal status. It’s included as background context, not as a pathway available to a Canadian researcher.
Semax was removed from FDA Category 2 restrictions in April 2026, and — critically — is specifically scheduled for a Pharmacy Compounding Advisory Committee review in July 2026, an active, ongoing evaluation that could result in it being added to the FDA’s approved compounding substances list.
Selank’s path diverged earlier and differently: it was removed from Category 2 back in September 2024, but because the original party who had nominated it for that restricted category withdrew the nomination entirely — not because it advanced toward a decision. Without an active nomination, there’s currently nothing for the FDA’s advisory committee to review, and no clear path toward a different classification unless someone restarts the nomination process.
The practical upshot, again strictly as US-specific background: Semax has a live regulatory process moving toward a decision; Selank currently doesn’t. Neither situation changes the actual Canadian legal picture, which is covered in our dedicated regulatory guide.
Practical Differences Worth Knowing
Timing flexibility differs meaningfully. Semax’s activating profile means morning administration is close to a hard rule in community practice — evening use risks disrupting sleep. Selank’s calming profile makes it considerably more flexible, usable in the morning for daytime anxiety support or in the evening for sleep-focused objectives.
Dosing structure differs slightly. Semax doesn’t have a strong community cycling convention — daily use, adjusted by individual response, is standard. Selank has a more defined community cycling pattern (4 weeks on, 4 weeks off) that’s treated as close to standard practice rather than optional.
Anti-doping status is more clearly established for one than the other. Semax is confirmed absent from the WADA Prohibited List as of April 2026. We were not able to independently confirm Selank’s status either way — worth confirming directly with a governing body if you’re subject to testing, rather than assuming parity with Semax.
Route considerations are similar for both — subcutaneous injection and intranasal administration are both used for either compound, with intranasal carrying the same theoretical CNS-delivery advantage via the olfactory pathway in both cases.
Which One Actually Fits Your Research Objective?
Choose Semax if: cognitive engagement, alertness, or focus during demanding work is your primary objective, and you’re comfortable with a compound that requires morning-only timing to avoid sleep disruption.
Choose Selank if: anxiety reduction or emotional steadiness is your primary objective, particularly if you want a calming effect without the sedation or dependency profile of a classical anxiolytic, and you want more flexibility in when you administer it.
Choose both together if: you want the community-described “calm focus” combination — Semax’s cognitive engagement without the edge, supported by Selank’s anxiety reduction. This is a widely discussed community pairing, not a clinically validated combination protocol.
Common Questions
Do Semax and Selank have the same legal status since they came from the same lab? No, as of 2026 — Semax has an active US regulatory review in progress; Selank’s nomination for that same process was withdrawn in 2024. This is US-specific and doesn’t affect Canadian legal status either way.
Which one has stronger evidence? Neither clearly outweighs the other — both have genuine, sustained Russian clinical development (Semax’s 1994 approval and three decades of use; Selank’s completed Phase III trial program) and the same Western evidence-quality limitations. They’re comparable in evidence strength, just for different indications.
Can I take these together? This is a commonly discussed community combination, generally described as complementary given their opposite primary effects. It’s a community pattern, not a clinically studied combination protocol.
Is either one going to become available as an approved drug in Canada or the US soon? Not imminently. Semax’s US compounding review is the more active regulatory process of the two, but “eligible for compounding under a prescription” is a different and much narrower outcome than full drug approval, and neither compound has anything resembling that closer step underway.
Where to Go From Here
- Semax: The Complete Guide
- Selank: The Complete Guide
- Our Canadian Regulatory Landscape Guide
- Our Reconstitution and Storage Guide
- Our Certificate of Analysis and Vendor Verification Guide
This guide reflects the evidence and regulatory information available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.
AETHON LABS — Tested. Documented. Delivered.